Previous issue | Volume 94 | ESPE2021

59th Annual ESPE (ESPE 2021 Online)

Online,
22 Sep 2021 - 26 Sep 2021

Card image cap
The 59th ESPE Annual Meeting will now be held online in September 2021.

ePoster Category 1

Growth B

Continued Safety and Efficacy of Weekly Lonapegsomatropin (TransCon hGH) for up to Two Years in Children with Growth Hormone Deficiency (GHD)
1Yerevan State Medical University, Yerevan, Armenia; 2Children’s Hospital at Dartmouth, Lebanon, USA; 3Center of Excellence in Diabetes and Endocrinology, Sacramento, USA; 4Liggins Institute, University of Auckland, Auckland, New Zealand; 5New York University Langone, Mineola, USA; 6Ascendis Pharma, Inc., Palo Alto, USA; 7Ascendis Pharma, A/S, Hellerup, Denmark; 8Cook Children’s Medical Center, Fort Worth, USA; 9Rocky Mountain Pediatric Endocrinology, Centennial, USA
hrp0094p1-161
Evaluation of growth patterns from the Edinburgh and Gothenburg cohorts by the QEPS model
1GP-GRC, Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 2Department of Pediatrics, Halland Hospital, Halmstad, Sweden; 3Department of Physiology/Endocrinology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 4Muvara bv, Multivariate Analysis of Research Data, Leiderdorp, Netherlands; 5UCL Great Ormond Street Institute of Child Health, and University College London Hospital, London, United Kingdom
hrp0094p1-162
The etiology of extreme tall stature above +3 SDS in a screened Finnish population
1Children’s Hospital, Helsinki University Hospital, Pediatric Research Center, Helsinki, Finland; 2Department of Physiology, Medicum Unit, Faculty of Medicine, and Stem Cells and Metabolism Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland
hrp0094p1-163
Long-term efficacy and safety of rhGH in children with SHOX deficiency: preliminary data of a national Italian survey (on behalf of ISPED Study Group on Growth Factors and Puberty).
1Department of Medical and Surgical Sciences of Mothers, Children and Adults, University of Modena & Reggio Emilia, Paediatric Unit, Modena, Italy; 2Pediatric Endocrinology, Regina Margherita Children’s Hospital, Turin, Italy; 3Units of Pediatrics, Department of Medical and Surgical Sciences, Policlinico St. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; 4Division of Paediatric Endocrinology and Diabetology, Paediatrics, Department of Mother and Child-AUSL of Reggio Emilia-IRCCS, Reggio Emilia, Italy; 5Anna Meyer Children’s University Hospital, Florence, Italy; 6Pediatric Unit, ASST Sette Laghi, Varese, Italy; 7Department of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy
hrp0094p1-164
Effects of age of start growth hormone treatment in children with Prader-Willi syndrome: The earlier the better?
1Dutch Reference Center for Prader-Willi Syndrome, Rotterdam, Netherlands; 2Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children’s Hospital, Rotterdam, Netherlands; 3Dutch Growth Research Foundation, Rotterdam, Netherlands
hrp0094p1-165
The BoneXpert adult height prediction method outperforms the Bayley and Pinneau method in tall male adolescents.
1UZ Brussel, Brussels, Belgium; 2Faculty of Medicine Ugent, Ghent, Belgium; 3UZ Gent, Ghent, Belgium; 4UZ Antwerpen, Antwerp, Belgium
hrp0094p1-166
Sex differences in growth response to GH treatment: more prepubertal and less pubertal gain in girls diagnosed with IGHD, ISS, SGA. Analysis of data from GH-SAFETY-database, including all children treated with rhGH- 1986-2009 in Sweden, in National-GH-Registry and rhGH-clinical-trials.
1Institute of Clinical Science/Pediatrics, Umeå University, Umea, Sweden; 2Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; 3Department of Physiology/Endocrinology, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
hrp0094p1-167
Mother’s smoking during pregnancy influence intrauterine and postnatal growth - the GrowUp 1990 Gothenburg cohort population
1GPGRC, Department of Pediatrics, Institute of Clinical, Gothenburg, Sweden; 2Department of Pediatrics, Halland Hospital, Halmstad, Sweden; 3Department of Physiology/Endocrinology, Institute of Neuroscience and Physiology, Gothenburg, Sweden
hrp0094p1-168
Safety of growth hormone and cardiovascular outcomes in patients with Noonan syndrome enrolled in NordiNet® International Outcome Study (IOS) and the ANSWER Program
1Department of Pediatrics, New York Medical College, New York, USA; 2Great Ormond Street Hospital, London, United Kingdom; 3UCL Institute of Cardiovascular Science, London, United Kingdom; 4Department of Paediatrics, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; 5Novo Nordisk Inc., Plainsboro, USA; 6Global Medical Affairs, Novo Nordisk Health Care AG, Zurich, Switzerland; 7Department of Pediatric Endocrinology, University Children’s Hospital, Saarland University Medical Center, Homburg, Germany; 8Paediatric Endocrinology, Diabetology and Gynaecology Department, Hôpital Universitaire Necker Enfants-Malades AP-HP, Paris, France; 9Université de Paris, Imagine Institute, Paris, France
hrp0094p1-169
Facilitating Telehealth In A Tertiary Paediatric Endocrine Service: A Quality Improvement Initiative To Reduce The Discrepancy Between Parent-reported And Auxologist Height Measurements
1Department of Paediatric Endocrinology and Diabetes, Great Ormond Street Hospital, London, United Kingdom; 2Genetics & Genomic Medicine Programme, University College London Great Ormond Street Institute of Child Health, London, United Kingdom
hrp0094p1-170